Remove Life Sciences Remove Medical Technology Remove Pharmaceuticals
article thumbnail

Honeywell, Salesforce Partner to Improve Outcomes in Life Sciences

HIT Consultant

to deliver a comprehensive platform of software solutions for the life sciences industry. Honeywell’s TrackWise Quality: Proactive Quality Management TrackWise Quality enables life sciences companies to transition from reactive to proactive quality management by building a comprehensive quality ecosystem. ”

article thumbnail

Salesforce Launches AI-Powered Life Sciences Cloud for Pharma and MedTech

HIT Consultant

What You Should Know: – Salesforce announced the general availability of Life Sciences Cloud , a platform for pharmaceutical ( pharma ) and medical technology ( medtech ) organizations to help personalize patient and healthcare professional (HCP) engagement and streamline clinical operations with data, automation, and trusted AI.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Person-Centered Interoperability Looks Like: Seqster

Health Populi

For wonky-tech readers, this involves using Seqster’s proprietary technology (FHIR+) to enable the flow of patient information from once-siloed data locked into legacy systems and wearable tech clouds.

article thumbnail

Real-World Data Flow – The Only Way to Change Value-Based Care?

HIT Consultant

With this in mind, it is critical that both payers and providers in VBC arrangements consider how their data flows through the entire system so that key partners, such as life sciences and pharmaceutical companies – have real-world insights (RWI) about the impact their medication is having on outcomes.

article thumbnail

The Role of Intellectual Property in the Biopharmaceutical Sector

Healthcare ECONOMIST

 In the context of this fast-moving political debate, FTI Consulting supported INTERPAT, a non-profit biopharmaceutical consortium, and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in developing a White Paper and peer-reviewed article on the role of IP in the biopharmaceutical sector.

article thumbnail

Quantifying the Long-Run Economic and Health Impact of Reduced Intellectual Property Protections for New Drugs

Healthcare ECONOMIST

Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical technologies, particularly in Eastern Europe and developing countries. The abstract is below.

article thumbnail

CPQ: Optimizing MedTech Operations and Sales to Accelerate Cash Flow

HIT Consultant

These inconsistencies and inaccuracies tend to compound in medical device and medical technology organizations where product portfolios are continually evolving, pricing fluctuates and quotes have to be configured to meet the specifications of each customer. But there are also some precautions to take with CPQ software.